Skip to main content
Premium Trial:

Request an Annual Quote

Syzygy Biotech Nabs $100K Investment for PCR Reagent Development

Premium

This article has been corrected from a previous version to correct misinformation regarding the current name of Syzygy Biotech.

Syzygy Biotech, a Grand Rapids, Mich.-based PCR reagents shop, has received a $100,000 investment from the Michigan Pre-Seed Capital Fund, fund administrator Ann Arbor Spark said today.

Syzygy, which was formed under the name Seedus Biotech, manufactures low-cost reagents such as Taq polymerases and master mixes for use in DNA amplification.

According to its website, the company is also currently developing a high-fidelity polymerase that it claims combines Taq's ease of use with equal or greater replication accuracy.

Syzygy is one of several companies to have recently received investments totaling about $1.8 million from the Michigan Pre-Seed Capital Fund, an equity fund administered by Ann Arbor Spark that invests in technology-based companies to support business formation and acceleration.

Last month, Syzygy also won a $100,000 SmartZone award at the Great Lakes Entrepreneur's Quest business plan contest held at Michigan State University. That award was also funded through the Michigan Pre-Seed Capital Fund.

Filed under

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.